vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and Vroom, Inc. (VRM). Click either name above to swap in a different company.
Vroom, Inc. is the larger business by last-quarter revenue ($235.9M vs $123.8M, roughly 1.9× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -59.8%, a 63.1% gap on every dollar of revenue. On growth, Vroom, Inc. posted the faster year-over-year revenue change (12.9% vs 4.7%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $-108.8M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -49.5%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Vroom, Inc. is a parent company of United Auto Credit Corporation (UACC) and CarStory. Previously, Vroom was a used car retailer and e-commerce company that let consumers buy, sell, and finance cars online. Vroom ceased e-commerce automotive sales operations on January 22, 2024.
NATR vs VRM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $235.9M |
| Net Profit | $4.1M | $-141.1M |
| Gross Margin | 72.5% | 12.3% |
| Operating Margin | 4.3% | -11.5% |
| Net Margin | 3.3% | -59.8% |
| Revenue YoY | 4.7% | 12.9% |
| Net Profit YoY | 1379.4% | -669.8% |
| EPS (diluted) | $0.23 | $-80.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | — | ||
| Q3 25 | $128.3M | — | ||
| Q2 25 | $114.8M | — | ||
| Q1 25 | $113.2M | — | ||
| Q4 24 | $118.2M | — | ||
| Q3 24 | $114.6M | — | ||
| Q2 24 | $110.6M | — | ||
| Q1 24 | $111.0M | — |
| Q4 25 | $4.1M | — | ||
| Q3 25 | $5.3M | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $-321.0K | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — | ||
| Q1 24 | 71.2% | — |
| Q4 25 | 4.3% | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 4.2% | — |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | $0.23 | — | ||
| Q3 25 | $0.30 | — | ||
| Q2 25 | $0.28 | — | ||
| Q1 25 | $0.25 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $0.23 | — | ||
| Q2 24 | $0.07 | — | ||
| Q1 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $135.6M |
| Total DebtLower is stronger | — | $454.2M |
| Stockholders' EquityBook value | $161.6M | $127.7M |
| Total Assets | $261.1M | $1.5B |
| Debt / EquityLower = less leverage | — | 3.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | — | ||
| Q3 25 | $95.6M | — | ||
| Q2 25 | $81.3M | — | ||
| Q1 25 | $86.5M | — | ||
| Q4 24 | $84.7M | — | ||
| Q3 24 | $78.7M | — | ||
| Q2 24 | $68.7M | — | ||
| Q1 24 | $77.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $166.7M | — | ||
| Q2 25 | $163.7M | — | ||
| Q1 25 | $167.1M | — | ||
| Q4 24 | $161.0M | — | ||
| Q3 24 | $162.6M | — | ||
| Q2 24 | $156.4M | — | ||
| Q1 24 | $159.7M | — |
| Q4 25 | $261.1M | — | ||
| Q3 25 | $264.8M | — | ||
| Q2 25 | $254.9M | — | ||
| Q1 25 | $252.7M | — | ||
| Q4 24 | $240.9M | — | ||
| Q3 24 | $245.3M | — | ||
| Q2 24 | $235.8M | — | ||
| Q1 24 | $247.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $-108.1M |
| Free Cash FlowOCF − Capex | $7.6M | $-108.8M |
| FCF MarginFCF / Revenue | 6.1% | -46.1% |
| Capex IntensityCapex / Revenue | 1.9% | 0.3% |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $-536.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | — | ||
| Q3 25 | $18.5M | — | ||
| Q2 25 | $4.3M | — | ||
| Q1 25 | $2.6M | — | ||
| Q4 24 | $12.2M | — | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $2.2M | — |
| Q4 25 | $7.6M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -1.4% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
VRM
Segment breakdown not available.
